Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
BRENTWOOD, Tenn., July 15, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 branded oral non-GLP-1 weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance.
According to the CDC, more than 40% of U.S. adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment.
"At Currax, we truly believe in access for all and putting patients at the center of everything we do," said George Hampton, CEO of Currax Pharmaceuticals. "By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health."
Obesity is one of the most pressing health challenges in the U.S., yet many people still struggle to access effective treatment. By combining Currax's clinical leadership in obesity care with GoodRx's reach and reputation for affordability, this collaboration removes a major barrier for patients who may not otherwise have access to FDA-approved medications. Together, the two companies are helping more people take control of their health with greater confidence and fewer hurdles.
"Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "By working with Currax to help consumers save money on Contrave, we're helping close this gap and delivering a simple affordability solution that improves access to a life-changing medication."
Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity.
For more information or to access the GoodRx Contrave savings card, visit: https://www.goodrx.com/contrave. *Program benefit maximums and eligibility restrictions may apply.
About CurraxCurrax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit www.curraxpharma.com.
About CONTRAVE:
CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes. For full Prescribing Information, including BOXED Warning and Medication Guide, please go to www.CONTRAVE.com.
Media Contactcurrax@ampublicrelations.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/currax-expands-access-to-fda-approved-obesity-treatment-with-brand-name-contrave-with-new-cash-price-available-via-goodrx-302505664.html
SOURCE Currax Pharmaceuticals LLC
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
18 minutes ago
- The Hill
Here are the cities where new college grads are landing jobs
For the second year in a row, Raleigh, N.C., tops the list of best U.S. cities for recent college graduates thanks to its job opportunities, comparatively affordable cost of living and strong hiring, according to a study from payroll provider ADP. ADP analyzed payroll data from more than 140,000 Americans ages 20 to 29 working at over 27,000 companies across the U.S. They then ranked 55 metro areas with at least one million residents based on hiring rates, average annual wages and affordability-adjusted wages. Here are the 5 best cities for new graduates, according to ADP: 1. Raleigh, N.C. Home to the Research Triangle, Raleigh continues to attract talent with its thriving tech industry and proximity to major universities, including Duke and the University of North Carolina, Chapel Hill. 2. Milwaukee The Milwaukee region rose to second place, thanks to a jump in its hiring rate from 2.3 percent to 3.7 percent. Annual wage: $49,208 Affordability-adjusted wage: $51,508 Hiring rate: 3.7 percent 3. Baltimore Though it dropped one spot from last year, Baltimore remains a strong market for new grads. Annual wage: $52,267 Affordability-adjusted wage: $50,907 Hiring rate: 3.5 percent 4. Austin, Texas Austin slipped from the No. 3 spot but still ranks high with solid wages and job prospects. Annual wage: $58,404 Affordability-adjusted wage: $59,828 Hiring rate: 2.8 percent 5. Birmingham, Ala. Birmingham made a big leap from No. 20 in 2024 to the top 5, thanks to affordability and rising job opportunities. Annual wage: $50,786 Affordability-adjusted wage: $54,863 Hiring rate: 2.8 percent 5. Denver Sunset on the Denver skyline looking west towards the Rocky Mountains. (Photo by: Joe Sohm/Visions of America/Universal Images Group via Getty Images) Denver also entered the top 5 this year, moving up from No. 11 in 2024. Annual wage: $59,094 Affordability-adjusted wage: $56,018 Hiring rate: 2.7 percent Meanwhile, Atlanta, which ranked higher in 2024, dropped due to a decline in its hiring rate to 2.2 percent. ADP's 5 worst cities for new grads in 2025: Portland, Oregon Hartford, Connecticut Riverside, California Salt Lake City, Utah Virginia Beach, Virginia
USA Today
18 minutes ago
- USA Today
Trump's approval rating drops to second-term low as support from independents craters
WASHINGTON ― President Donald Trump's approval rating has dropped to 37%, according to a new Gallup poll, the lowest mark of his second term as independent voters have increasingly soured on his presidency. The poll, taken July 7 through July 21, was conducted on the heels of Trump's July 4 signing of his "Big, Beautiful Bill" into law and as he's faced an intense backlash over his administration's refusal to release files in the government's case of disgraced financier and sex offender Jeffrey Epstein. It marks a 10-point drop from the 47% approval rating Americans gave Trump's job performance at the beginning of his term in January. The poll, a phone survey of 1,002 Americans, has a margin of error of +/- 4 percentage points. More: Trump tussles with Powell during Federal Reserve visit but backs off firing threat Only 29% of independent voters said they approved of Trump's job performance, a 17-point decline from the 46% the president enjoyed among independents at the start of his second term. The 29% approval rating among independent voters is the lowest Gallup has tracked with the group in either of his two terms. Trump has maintained strong support from Republican voters ‒ dropping just one point from 90% in January to 89% ‒ while backing from Democratic voters has slid from 6% to 2%. Trump's approval rating slides on issues including economy An average of recent polls from Real Clear Politics found Trump with a higher approval rating of 52%, compared to 46% of Americans who approve of his job performance. Although Trump's "Big, Beautiful Bill" legislation marked a major legislative victory for the president, a CNN poll conducted by SSRS this month found 61% of Americans opposed the megabill, which includes cuts to Medicaid and food stamps and an extension of Trump's 2017 tax cuts estimated to add $3.3 trillion to the debt over 10 years. Trump has also lost support on his handling of most issues. Only 37% of Americans approved of his handling of the economy in July, down from 42% in Gallup's February poll. Trump's favorability rating on immigration decreased from 46% to 38%, his handling of foreign trade from 42% to 36%, his handling of foreign affairs from 44% to 41%, and his handling of the Middle East from 40% to 36%. More: Trump says he hasn't considered pardoning Epstein associate Ghislaine Maxwell Trump's lowest approval marks are for his handling of the war in Ukraine, 33%, and the federal budget, 29%. More: Trump signs order pushing cities and states to remove homeless people from streets Trump's average approval rating in Gallup polls between April 20 and July 19, was 40% ‒ significantly below the 59% average for all post-World War II presidents elected from 1952 to 2020 at the same point in their first terms. Yet it was a notch above the 39% first-term second-quarter average Trump had in 2017. The latest Gallup poll is a potential warning sign for Trump and Republicans more than one year away from the 2026 midterms, when Democrats hope to win back control of the House of Representatives and Senate. Yet Trump has proven in the past that he has the strength political to overcome poor polling. Trump's lowest approval rating, 34%, came at the end of his first term in January 2021 after he refused to concede the 2020 election and the Jan. 6 attack on the U.S. Capitol. Reach Joey Garrison on X @joeygarrison.
CNBC
21 minutes ago
- CNBC
Trump floats tariff 'rebate' for consumers. That could be a challenge, experts say
President Donald Trump said the administration is considering a rebate for some consumers from revenue raised by higher tariffs on U.S. trade partners. When asked by a reporter on Friday at the White House about a possible rebate for Americans from tariff revenue, Trump said: "We're thinking about that. We have so much money coming in, we're thinking about a little rebate." "The big thing we want to do is pay down debt," Trump said. "But we're thinking about a rebate." "A little rebate for people of a certain income level might be very nice," he said. It's unclear whether a rebate could happen without Congressional approval. If enacted, it's unknown whether the rebate would come via stimulus checks or another form of tax relief, experts say. More from Personal Finance:Student loan forgiveness may soon be taxed againWhat the Fed's interest-rate decision could mean for your moneyHow to lower capital gains on your home sale as Trump eyes ending the tax "It's kind of unlikely that they would go ahead and do that," said Tax Foundation senior economist Alex Durante. "But I wouldn't put anything past this administration." The Treasury Department reported an unexpected surplus for June, with a boost from tariff revenue. Customs duties totaled roughly $27 billion for the month, compared to $23 billion in May. The duties reflect a 301% gain from June 2024. Trump's rebate idea comes as a chorus of lawmakers and policy experts voice concerns about the federal budget deficit. "I don't think [a rebate] would be particularly good policy," Durante said. "I would prefer that the revenue was used for deficit reduction rather than just cutting checks to people." Enacted in early July, Trump's "one big beautiful" tax-and-spending package could add an estimated $3.4 trillion to the deficit through 2034, according to a conventional score released by the Congressional Budget Office this week. The motivation for sending the direct payments would be different than they were during the Covid pandemic, when many households were losing income or unable to work, said Joseph Rosenberg, senior fellow at the Urban-Brookings Tax Policy Center's tax and income supports division. Now, the federal government is imposing tariffs that will cost U.S. households, and this would be a way of helping those individuals and families, Rosenberg said. Because Congress just passed the very expensive "big beautiful" budget and tax legislation, rebates to individuals could exacerbate the effects on the federal budget deficit, he said. The rebates would reinforce the inflationary effects of the tariffs that already exist, Rosenberg said. "People will go out and spend some of that money, and that would further put upward pressure on prices and probably magnify inflationary effects," Rosenberg said. Pandemic-era fiscal stimulus contributed to an increase in inflation of about 2.6 percentage points in the U.S., according to 2023 research from the Federal Reserve Bank of St. Louis.
